Home Featured Page 238

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Bright Minds Biosciences Announces Application to List on Nasdaq

Whole-Body Effects of Psychedelics – Part 1

Optimi Health Completes Pre-Clinical Trial Application Meeting

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™...

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch...

PT248 – Pierre Bouchard – Somatic Therapy, Trauma, and the Nervous...

Psychedelic Research Bulletin: May 2021

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

1...237238239...296 Page 238 of 296

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Bright Minds Biosciences Announces Application to List on Nasdaq

Whole-Body Effects of Psychedelics – Part 1

Optimi Health Completes Pre-Clinical Trial Application Meeting

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™...

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch...

PT248 – Pierre Bouchard – Somatic Therapy, Trauma, and the Nervous...

Psychedelic Research Bulletin: May 2021

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY